Cyprotex PLC Launch of GLP-Compliant Genotoxicity Services
26 April 2016 - 4:01PM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
26 April 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Launch of GLP-Compliant Genotoxicity Services
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience
Contract Research Organisation, today announces the launch of
GLP-compliant genotoxicity services. The new services will be
offered from its Kalamazoo laboratories in Michigan in the USA.
This site is already GLP-compliant and offers a number of other
regulatory tests for determining skin absorption and skin and
ocular toxicity as well as endocrine disruption.
Within the facility, a range of new genotoxicity services have
been fully validated according to OECD test guidelines. The
services include the bacterial reverse mutation test, otherwise
known as the Ames test (OECD test guideline 471) and the in vitro
micronucleus test (OECD test guideline 487). The in vitro mammalian
chromosome aberration test (OECD test guideline 473) will follow
shortly after. These methods cover a number of different genotoxic
mechanisms, and form a panel of in vitro protocols which are
accepted by regulatory authorities.
A number of different industries rely on genotoxicity testing
for evaluating potential risk to human health, and it is a
regulatory requirement in the pharmaceutical, veterinary, chemical,
pesticide and cosmetics and personal care industries. All these
industries now incorporate in vitro methods into their testing
cascade for genotoxicity assessment. Having robust GLP- compliant
methods which follow recommended guidelines is critical for
submission of these data to the regulatory authorities.
Anthony Baxter PhD, Chief Executive Officer of Cyprotex,
comments on the launch of the new genotoxicity services,
'Genotoxicity testing is a regulatory requirement within a number
of different industries. In vitro genotoxicity methods are now
acceptable alternatives, either to completely replace animal
testing as is the case with cosmetics products in Europe, or to be
used within a testing battery to reduce the use of animals as is
the case for pharmaceuticals or pesticide products. By introducing
a suite of GLP compliant genotoxicity services, Cyprotex is
addressing the needs of these markets for high quality regulatory
accepted methods.'
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1400 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGZDFKNGVZM
(END) Dow Jones Newswires
April 26, 2016 02:01 ET (06:01 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024